title: Readthrough of stop codons by use of aminoglycosides in cells from xeroderma pigmentosum group C patients.
abstract: Readthrough of premature termination (stop) codons (PTC) is a new approach to treatment of genetic diseases. We recently reported that readthrough of PTC in cells from some xeroderma pigmentosum complementation group C (XP-C) patients could be achieved with the aminoglycosides geneticin or gentamicin. We found that the response depended on several factors including the PTC sequence, its location within the gene and the aminoglycoside used. Here, we extended these studies to investigate the effects of other aminoglycosides that are already on the market. We reasoned that topical treatment could deliver much higher concentrations of drug to the skin, the therapeutic target, and thus increase the therapeutic effect while reducing renal or ototoxicity in comparison with systemic treatment. Our prior clinical studies indicated that only a few percent of normal XPC expression was associated with mild clinical disease. We found minimal cell toxicity in the XP-C cells with several aminoglycosides. We found increased XPC mRNA expression in PTC-containing XP-C cells with G418, paromomycin, neomycin and kanamycin and increased XPC protein expression with G418. We conclude that in selected patients with XP, topical PTC therapy can be investigated as a method of personalized medicine to alleviate their cutaneous symptoms.
authors: Dermatology Branch, NCI, Bethesda, MD, USA.
authors: Christiane
authors: C
authors: Kuschal
authors: Sikandar G
authors: SG
authors: Khan
authors: Benedikt
authors: B
authors: Enk
authors: John J
authors: JJ
authors: DiGiovanna
authors: Kenneth H
authors: KH
authors: Kraemer
mesh_terms: D000287:Administration, Topical; D000617:Aminoglycosides / Q000008:administration & dosage / Q000494:pharmacology*; D002478:Cells, Cultured; D018389:Codon, Nonsense / Q000187:drug effects; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D050505:Mutant Proteins / Q000235:genetics / Q000378:metabolism; D057285:Precision Medicine; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014983:Xeroderma Pigmentosum / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism
chemical_list: D000617:Aminoglycosides; D018389:Codon, Nonsense; D004268:DNA-Binding Proteins; D005839:Gentamicins; D050505:Mutant Proteins; D012333:RNA, Messenger; C086984:XPC protein, human; C010680:antibiotic G 418
keywords: DNA repair; aminoglycosides; premature termination codons; skin cancer; xeroderma pigmentosum
references: Hum Mol Genet. 2004 Feb 1;13(3):343-52
references: 14662655
references: J Invest Dermatol. 2006 Jan;126(1):229-31
references: 16417242
references: Hum Mutat. 2010 Feb;31(2):167-75
references: 19953607
references: J Invest Dermatol. 2012 Mar;132(3 Pt 2):785-96
references: 22217736
references: Pharmacol Ther. 2012 Nov;136(2):227-66
references: 22820013
references: PLoS One. 2013 Apr 10;8(4):e60478
references: 23593225
references: Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19483-8
references: 24218596
references: Mol Cells. 2014 Jan;37(1):1-8
references: 24552703
references: Mol Ther. 2014 Oct;22(10):1741-52
references: 25155989